Fig. 2: Invasive fungal disease (IFD) in the different treatment phases (protocol I, II, III and HR cycles, respectively) in standard (SR) and intermedium risk (MR) patients (above) and high risk (HR) patients (below). | Leukemia

Fig. 2: Invasive fungal disease (IFD) in the different treatment phases (protocol I, II, III and HR cycles, respectively) in standard (SR) and intermedium risk (MR) patients (above) and high risk (HR) patients (below).

From: Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009

Fig. 2

Shown are the absolute number of possible (blue), probable and proven yeast (orange) and probable/proven mold (grey) infections (Y axis). The percentages refer to the total number of IFDs in the respective risk groups (SR/MR and HR).

Back to article page